Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

USA - NASDAQ:ZVRA - US4884452065 - Common Stock

7.75 USD
-0.2 (-2.52%)
Last: 9/12/2025, 8:27:14 PM
7.95 USD
+0.2 (+2.58%)
After Hours: 9/12/2025, 8:27:14 PM
Fundamental Rating

4

ZVRA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. ZVRA may be in some trouble as it scores bad on both profitability and health. ZVRA is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ZVRA has reported negative net income.
ZVRA had a negative operating cash flow in the past year.
In the past 5 years ZVRA always reported negative net income.
ZVRA had negative operating cash flow in 4 of the past 5 years.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

ZVRA has a Return On Assets of 1.03%. This is amongst the best in the industry. ZVRA outperforms 81.12% of its industry peers.
With an excellent Return On Equity value of 2.26%, ZVRA belongs to the best of the industry, outperforming 83.67% of the companies in the same industry.
Industry RankSector Rank
ROA 1.03%
ROE 2.26%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

ZVRA's Profit Margin of 4.26% is amongst the best of the industry. ZVRA outperforms 83.16% of its industry peers.
Looking at the Gross Margin, with a value of 89.69%, ZVRA belongs to the top of the industry, outperforming 93.88% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 4.26%
GM 89.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZVRA has more shares outstanding
Compared to 5 years ago, ZVRA has more shares outstanding
ZVRA has a worse debt/assets ratio than last year.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.10, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
ZVRA has a Altman-Z score (-0.10) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.52 indicates that ZVRA is somewhat dependend on debt financing.
ZVRA has a Debt to Equity ratio of 0.52. This is in the lower half of the industry: ZVRA underperforms 60.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACC10.12%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

ZVRA has a Current Ratio of 7.85. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA has a Current ratio of 7.85. This is in the better half of the industry: ZVRA outperforms 77.55% of its industry peers.
ZVRA has a Quick Ratio of 7.81. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA has a Quick ratio of 7.81. This is in the better half of the industry: ZVRA outperforms 77.55% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.81
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.31% over the past year.
Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 158.51%.
The Revenue has been growing by 12.96% on average over the past years. This is quite good.
EPS 1Y (TTM)86.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%352.08%
Revenue 1Y (TTM)158.51%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%481.73%

3.2 Future

Based on estimates for the next years, ZVRA will show a very strong growth in Earnings Per Share. The EPS will grow by 30.19% on average per year.
Based on estimates for the next years, ZVRA will show a very strong growth in Revenue. The Revenue will grow by 80.69% on average per year.
EPS Next Y130.61%
EPS Next 2Y50.93%
EPS Next 3Y41.2%
EPS Next 5Y30.19%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ZVRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 12.33 indicates a correct valuation of ZVRA.
Based on the Price/Forward Earnings ratio, ZVRA is valued cheaply inside the industry as 84.69% of the companies are valued more expensively.
ZVRA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.73, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 12.33
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

ZVRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 41.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.93%
EPS Next 3Y41.2%

More info and screens

0

5. Dividend

5.1 Amount

ZVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (9/12/2025, 8:27:14 PM)

After market: 7.95 +0.2 (+2.58%)

7.75

-0.2 (-2.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners63.31%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change13.05%
Market Cap435.08M
Analysts84.29
Price Target24.19 (212.13%)
Short Float %11.55%
Short Ratio4.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.84%
Min EPS beat(2)-20.8%
Max EPS beat(2)68.49%
EPS beat(4)1
Avg EPS beat(4)-20.06%
Min EPS beat(4)-67.34%
Max EPS beat(4)68.49%
EPS beat(8)2
Avg EPS beat(8)-18.58%
EPS beat(12)3
Avg EPS beat(12)-18.77%
EPS beat(16)5
Avg EPS beat(16)-14.97%
Revenue beat(2)2
Avg Revenue beat(2)15.27%
Min Revenue beat(2)12.59%
Max Revenue beat(2)17.95%
Revenue beat(4)3
Avg Revenue beat(4)9.31%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)13.34%
Revenue beat(16)9
Avg Revenue beat(16)9.96%
PT rev (1m)-0.6%
PT rev (3m)5.73%
EPS NQ rev (1m)46.87%
EPS NQ rev (3m)70.83%
EPS NY rev (1m)-27.57%
EPS NY rev (3m)2.58%
Revenue NQ rev (1m)9.56%
Revenue NQ rev (3m)7.93%
Revenue NY rev (1m)8.3%
Revenue NY rev (3m)16.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.33
P/S 7.02
P/FCF N/A
P/OCF N/A
P/B 3.71
P/tB 4.12
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.63
Fwd EY8.11%
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS1.1
BVpS2.09
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.03%
ROE 2.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.26%
GM 89.69%
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.15%
Cap/Sales 10.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.81
Altman-Z -0.1
F-Score5
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%352.08%
EPS Next Y130.61%
EPS Next 2Y50.93%
EPS Next 3Y41.2%
EPS Next 5Y30.19%
Revenue 1Y (TTM)158.51%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%481.73%
Revenue Next Year392.47%
Revenue Next 2Y175.62%
Revenue Next 3Y130.52%
Revenue Next 5Y80.69%
EBIT growth 1Y18.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.79%
EBIT Next 3Y40.08%
EBIT Next 5Y33.33%
FCF growth 1Y-119.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3YN/A
OCF growth 5YN/A